TFK-1Homo sapiens (Human)Cancer cell line

Also known as: TFK1, TFKK-1 (In supplementary figure 2.)

🤖 AI SummaryBased on 4 publications

Quick Overview

Human extrahepatic bile duct carcinoma cell line with epithelial morphology and specific marker expression.

Detailed Summary

TFK-1 is a human extrahepatic bile duct carcinoma cell line established from a surgically resected tumor specimen. It exhibits typical epithelial morphology, forming polygonal monolayers with pavement-like cell arrangement. The cells show a population doubling time of 37 hours during exponential growth. Chromosome analysis reveals a modal number of 73, with a range of 72-76. TFK-1 cells do not secrete common tumor markers such as CEA, CA19-9, ST-439, or DUPAN-2, but express the c-erbB-2 protein and MUC1 antigen. The cell line has been maintained for 44 months (75 passages) in culture and retains characteristics of the original tumor upon xenografting in SCID mice. TFK-1 provides a valuable in vitro model for studying extrahepatic bile duct carcinoma biology and therapeutic strategies.

Research Applications

Cancer biology researchDrug screeningTumor marker analysisMolecular characterization

Key Characteristics

Epithelial morphologyNo secretion of CEA, CA19-9, ST-439, DUPAN-2Expression of c-erbB-2 and MUC1Xenograft tumor formationStable in long-term culture

Generated on 6/18/2025

Basic Information

Database ID	CVCL_2214
Species	Homo sapiens (Human)
Tissue Source	Extrahepatic bile duct[UBERON:UBERON_0003703]

Donor Information

Age	63
Age Category	Adult
Sex	Male

Disease Information

Disease	Cholangiocarcinoma
Lineage	Biliary Tract
Subtype	Extrahepatic Cholangiocarcinoma
OncoTree Code	EHCH

DepMap Information

Source Type	DSMZ
Source ID	ACH-001673_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Trp91Ter (c.272G>A)	Heterozygous	-	PubMed=21528241

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

D13S317

D16S539

D18S51

D19S433

14,15

D21S11

D2S1338

18,22

D3S1358

17,18

D5S818

9,12

D7S820

D8S1179

13,14

FGA

20,23

Penta D

13,14

Penta E

5,18

TH01

TPOX

vWA

14,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets.

Vazquez F., Getz G., Bardeesy N.M.

bioRxiv 2024:07.04.601970-07.04.601970(2024).

DOI PubMed PMC

Development and characterization of human primary cholangiocarcinoma cell lines.

Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.

Am. J. Pathol. 192:1200-1217(2022).

DOI PubMed PMC

RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling.

Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.

Cancers (Basel) 12:2510.1-2510.14(2020).

DOI PubMed PMC

Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.

Jirawatnotai S.

Hepatology 70:1614-1630(2019).

DOI PubMed

Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.

Bardeesy N.M.

Cancer Discov. 6:727-739(2016).

DOI PubMed PMC

DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.

Ishida M., Motoi F., Egawa S., Unno M., Horii A.

Biochem. Biophys. Res. Commun. 421:98-104(2012).

DOI PubMed

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

DOI PubMed

Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.

Fukuhara K., Suzuki T., Matsuno S.

Tohoku J. Exp. Med. 177:61-71(1995).

DOI PubMed